This edition of the Newsletter also includes the recommendations from the 42nd Annual Meeting of Representatives of National Pharmacovigilance Centres participating in the WHO Programme for International Drug Monitoring. Given the current interest over the use of chloroquine and hydroxychloroquine in COVID-19, we have also included a summary of case safety reports in Vigibase for these products.

 

Posted on the WHO website on 19 May 2020